盤中異動 | 復星醫藥盤中下跌10%,報於32.6港元
2021年11月8日9時36分,復星醫藥(HK02196)盤中下跌10%,報於32.6港元,成交額達5810.64萬港元,換手率達到0.06%。
11月7日訊,11月7日據每經,復星凱特執行總裁黃海表示,當下復星凱特主要致力於提高兩方面的能力,首先正在儘可能降低奕凱達的定價;其次也在積極地將產品推向各地的醫保體系內。目前,蘇州的惠民保、北京的京惠保、長沙的愛民保等都已經把奕凱達納入,同時我們也期待着在政府以及社會各界的共同努力之下,能夠讓它的可及性最大化併發揮產品的療效,實現它的社會價值。
11月1日,裏昂:重申覆星醫藥(02196)“買入”評級,目標價微升至67.6港元。10月22日,國泰君安:新冠疫苗進入業績兌現期,2021年全球銷售額有望突破千億美元。
最新的財務數據顯示,公司於2021年3季度,營業收入100.96億人民幣,淨利潤11.81億人民幣;營業收入同比增加26.84%,毛利潤同比增加6.74%,淨利潤同比增加40.59%。
盈立趨勢長盈模型最近一次交易信號,2021年11月3日出現關注信號,觸發價格爲36.8港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
![](/hk/assets/image/code.84ab0b.png)
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.